Showing 3591-3600 of 5773 results for "".
- Ocuphire Pharma Submits New Drug Application to FDA for Nyxol Eye Drops for Reversal of Mydriasishttps://modernod.com/news/ocuphire-pharma-submits-new-drug-application-to-fda-for-nyxol-eye-drops-for-reversal-of-mydriasis/2481278/Ocuphire Pharma announced the submission of a new drug application (NDA) to the FDA for Phentolamine Ophthalmic Solution 0.75% (Nyxol) for the reversal of pharmacologically-induced mydriasis (RM) produced by adrenergic agonist (e.g., phenylephrine) or parasympatholytic (e.g., tropicamid
- Sifi Launches EpiColin Glaucoma Supplement in Italyhttps://modernod.com/news/sifi-launches-epicolin-glaucoma-supplement-in-italy/2481276/Sifi announced the launch in Italy of EpiColin, a food supplement dedicated to patients suffering from glaucoma. Following Amiriox and Ecbirio, IOP drugs fully reimbursed by the Italian NHS, EpiColin is the third innovation in the glaucoma therapeutic area introduced by Sifi in th
- Genentech Launches Phase 2a Study of RG6501 (OpRegen) in Patients With Geographic Atrophyhttps://modernod.com/news/genentech-launches-phase-2a-study-of-rg6501-opregen-in-patients-with-geographic-atrophy/2481274/Lineage Cell Therapeutics announced that its partner Genentech has
- iSTAR Medical Expands Commercial Rollout of MINIject with First Surgeries in Sweden and Norwayhttps://modernod.com/news/istar-medical-expands-commercial-rollout-of-miniject-with-first-surgeries-in-sweden-and-norway/2481272/iSTAR Medical announced that the commercial rollout expansion for MINIject has continued with the first implantations performed in Sweden and Norway. MINIject is iSTAR Medical’s minimally-invasive glaucoma surgery (MIGS) implant and is currently the only commerciall
- NeoLight Launches ROP Risk Management Software ROPCheck.comhttps://modernod.com/news/neolight-launches-rop-risk-management-software-ropcheckcom/2481271/NeoLight announced that it is releasing ROP Check, a software used in digital care coordination for pediatric retinal screening to detect and monitor progression of retinopathy of prematurity (ROP). The launch comes 1 year after NeoLight acquired Phoenix Technology Group, which bro
- Cognition Therapeutics Presents Data Supporting a Phase 2 Clinical Trial with CT1812 in Geographic Atrophy Secondary to Dry AMDhttps://modernod.com/news/cognition-therapeutics-presents-data-supporting-a-phase-2-clinical-trial-with-ct1812-in-geographic-atrophy-secondary-to-dry-amd/2481270/Cognition Therapeutics announced that the scientific rationale, supporting proof-of-concept data and design of the planned phase 2 trial of CT1812 in geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD) will be communicated in an oral presentation at the
- Opus Genetics Receives FDA Clearance of IND Application for Gene Therapy Candidate for Rare Inherited Retinal Disease LCA5https://modernod.com/news/opus-genetics-receives-fda-clearance-of-ind-application-for-opgx-001-a-gene-therapy-candidate-for-the-treatment-of-rare-inherited-retinal-disease-lca5/2481268/Opus Genetics announced the FDA has cleared its investigational new drug (IND) application for a phase 1/2, first-in-human clinical trial of OPGx-001 in patients with Leber congenital amaurosis (LCA) resulting from biallelic mutations in the LCA5 gene (LCA5). OPGx-001 is an adeno-a
- Harrow and iOR Partners Expand National Product Supply Agreementhttps://modernod.com/news/harrow-and-ior-partners-expand-national-product-supply-agreement/2481267/Harrow and iOR Partners jointly announced the expansion of their national product supply agreement to provide Harrow’s entire formulary compounded ophthalmic products to iOR Partners’ expanding office-based surgery locations across the United States.</
- Re-Vana Therapeutics Raises $11.9 Million to Advance Drug Delivery Productshttps://modernod.com/news/re-vana-therapeutics-raises-119-million-to-advance-drug-delivery-products/2481266/Re-Vana Therapeutics announced the closure of its Series A round with $11.9 million in funding, an oversubscription of $4 million. The proceeds will advance the development of Re-Vana's novel and proprietary photo-crosslinked EyeLief, EyeLief-SD, and OcuLief 
- Ripple Therapeutics Appoints Jonathan Talamo, MD, to Chair of the Boardhttps://modernod.com/news/ripple-therapeutics-appoints-jonathan-talamo-md-to-chair-of-the-board/2481265/Ripple Therapeutics announced that Jonathan Talamo, MD, has been appointed as the new Chair of its Board of Directors. Dr. Talamo is internationally known as an experienced surgeon and thought leader in ophthalmology. Following 25 years in clinical practice, Dr. Talamo s